Option chain shows key data for Knight Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Knight Therapeutics.

Knight Therapeutics (OTC:KHTRF) Stock, Option Chain

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

News

Penny Stocks

Small Cap

KHTRF

RIGL

TSX:GUD

Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF) 

Knight Therapeutics Secures Rights To Rigel&#39;s Fostamatinib In Latin America

Biotech

Health Care

Contracts

General

PBYI

Puma Biotech&#39;s Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

Intraday Update

Markets

Movers

Trading Ideas

ABCE

ACST

AIPUY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALTM

AMADF

AMCX

ANLDF

ANZFF

APTS

APVO

AQARF

ARCH

ASBRF

ASIX

ATRO

ATROB

ATUSF

AWCMY

AXION VENTURES INC by Axion Ventures Inc.

AXNVF

BBDO

BBSI

BCII

BFCH

BKUCF

BMMJ

BORR

BPAQF

BPMP

BRID

BRRAY

BUHPF

CANNABIS ONE HLDGS INC by Cannabis One Holdings Inc.

CAAOF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CCDBF

CCLLF

CCLP

CDEV

CEQP

CHOOF

CHRRF

CJPRY

CJREF

CLDT

CLVLY

CNDT

CNXM

COKE

CRON

CWBHF

CWYUF

CYBL

DAKT

DCIX

DGEAF

DLNDY

DLTH

DNKLY

DRTT

EARS

EBIX

ECAOF

EMERALD HEALTH THERAPUTCS by Emerald Health Therapeutics Inc.

EMHTF

ENBL

ENLC

ENOB

FRONTERA ENERGY CORP ORD by Frontera Energy Corp

FECCF

FLNG

Stocks That Hit 52-Week Lows On Wednesday

KNIGHT THERAPEUTICS INC by Knight Therapeutics Inc

Knight Therapeutics Inc

Raymond James analyst David Novak maintains Knight Therapeutics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KHTRF#OTC">KHTRF</a>) with a Outperform and raises the price target from $7 to $7.5.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Knight Therapeutics, Raises Price Target to $7.5

Knight Therapeutics Inc.&nbsp;(TSX: GUD) (OTC: <a class="ticker" href="https://www.benzinga.com/stock/khtrf#OTC">KHTRF</a>)&nbsp;<a class="editor-rtfLink" href="https://gudknight.irpass.com/Knight-Therapeutics-Enters-into-Exclusive-License-and-Supply-Agreements-with-Rigel-Pharmaceuticals-to-Commercialize-Fostamatinib-in-Latin-America-5-24-2022" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">entered into exclusive license and supply agreements&nbsp;</a>with&nbsp;Rigel Pharmaceuticals&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rigl#NASDAQ">RIGL</a>), securing the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE (fostamatinib disodium hexahydrate) and in Europe under the brand name TAVLESSE for the treatment of chronic immune thrombocytopenia (ITP).
Fostamatinib is also currently being studied in a Phase 3 clinical trial for the treatment of warm autoimmune hemolytic anemia (wAIHA) and in two Phase 3 clinical trials for the treatment of hospitalized patients with COVID-19.
Rigel will receive an upfront cash payment. Knight gains exclusive rights to fostamatinib in all prospective indications in Latin America, including chronic ITP, wAIHA, and COVID-19.
&quot;This partnership represents the continued execution of our strategy of leveraging our solid platform and expertise to bring innovative medicines to our markets,&quot; stated Samira Sakhia, President and CEO of Knight.&nbsp;
Price Action:&nbsp;GUD shares closed higher by 0.19% at C$5.32&nbsp;on TSX on Tuesday.
Photo Via Company

Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America

<ul>
<li><a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/07/g21853493/knight-therapeutics-announces-health-canada-approval-for-nerlynx-neratinib-to-treat-her2-positive-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Health Canada has approved</a>&nbsp;Puma Biotechnology Inc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbyi#NASDAQ">PBYI</a>) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.</li>
<li>Knight Therapeutics Inc&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/khtrf#OTC">KHTRF</a>) has the exclusive right to commercialize Nerlynx in Canada.</li>
<li>Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2, and HER4.&nbsp;</li>
<li>Price Action:&nbsp;PBYI shares are down 2.49% at $8.60 during the market session on the last check Tuesday.</li>
</ul>

Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

Pre-open movers
US stock futures traded higher in early pre-market trade. The PMI manufacturing index for December will be released at 8:58 a.m. ET, while the ISM manufacturing composite index for December and construction spending data for November will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 65 points to 17,817.00, while the Standard &amp; Poor's 500 index futures rose 6.70 points to 2,059.10. Futures for the Nasdaq 100 index climbed 14.50 points to 4,247.25.
A Peek Into Global Markets
European markets were mostly lower today, with the Spanish Ibex Index gaining 0.78%, STOXX Europe 600 Index falling 0.25% and German DAX 30 index dropping 0.79%. French CAC 40 Index declined 0.37% and London's FTSE 100 Index fell 0.14%. Eurozone's manufacturing PMI climbed to 50.6 in December, versus 50.1 in November.
In Asian markets, Hong Kong's Hang Seng Index gained 1.07% and India's Sensex jumped 1.38%.
Broker Recommendation 
Analysts at Canaccord Genuity upgraded Bed Bath &amp; Beyond Inc. (NASDAQ: <a class="ticker" href="/stock/bbby#NASDAQ">BBBY</a>) from Hold to Buy. The price target for Bed Bath &amp; Beyond has been raised from $66 to $91. 
Bed Bath &amp; Beyond's shares closed at $76.17 on Wednesday.
Breaking news 
<ul>
<li> Cesca Therapeutics Inc. (NASDAQ: <a class="ticker" href="/stock/kool#NASDAQ">KOOL</a>) today announced that it has received a letter from the U.S. Food and Drug Administration responding to the Company's investigational device exemption ("IDE") application for its pivotal CLIRST III clinical trial. To read the full news, <a href="http://www.benzinga.com/news/15/01/5114953/update-cesca-receives-feedback-from-the-fda-on-its-pivotal-investigational-device">click here. </a></li>
<li> Knight Therapeutics Inc. (OTC: <a class="ticker" href="/stock/khtrf#OTC">KHTRF</a>) today announced that it has entered into a strategic partnership with NeurAxon Inc. for the commercialization of NeurAxon's innovative products in various stages of development in Canada, Israel, South Africa and Russia. To read the full news, <a href="http://www.benzinga.com/pressreleases/15/01/m5114518/knight-therapeutics-inc-and-neuraxon-inc-form-partnership-for-the-comme">click here.</a></li>
<li> Eli Lilly and Company (NYSE: <a class="ticker" href="/stock/lly#NYSE">LLY</a>) today announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly's Elanco as a global leader in the animal health industry. To read the full news, <a href="http://www.benzinga.com/pressreleases/15/01/n5114377/lilly-finalizes-novartis-animal-health-acquisition">click here.</a></li>
<li> Hilltop Holdings Inc. (NYSE: <a class="ticker" href="/stock/hth#NYSE">HTH</a>), the parent company of PlainsCapital Corporation, today announced that it has completed its acquisition of Dallas-based SWS Group, Inc. To read the full news, <a href="http://www.benzinga.com/pressreleases/15/01/b5114517/hilltop-holdings-inc-completes-acquisition-of-sws-group-inc">click here.</a></li>
</ul>

Eurozone

Futures

Global

Pre-Market Outlook

BBBY

KOOL

US Stock Futures Surge Ahead Of Manufacturing Data

Knight Therapeutics Inc. (OTC: <a class="ticker" href="/stock/khtrf#OTC">KHTRF</a>) today announced that it has entered into a strategic partnership with NeurAxon Inc. for the commercialization of NeurAxon's innovative products in various stages of development in Canada, Israel, South Africa and Russia. Under this partnership, Knight will pay approximately $1.75 million cash and provide additional&hellip;Knight Therapeutics Inc. (OTC: <a class="ticker" href="/stock/khtrf#OTC">KHTRF</a>) today announced that it has entered into a strategic partnership with NeurAxon Inc. for the commercialization of NeurAxon's innovative products in various stages of development in Canada, Israel, South Africa and Russia. Under this partnership, Knight will pay approximately $1.75 million cash and provide additional funding to further develop the Pharmaceuticals. A new company will be formed called NeurAxon Pharma Inc. ("NeurAxon Pharma") which will own the Pharmaceuticals for all markets except the Territory and will continue the development of the clinical portfolio. "We are pleased to partner with NeurAxon for the development and commercialization of their portfolio of pre-clinical and clinical products. NeurAxon has shown that their nitric oxide synthase inhibitors ("NOS") are safe and show clinical markers for efficacy in migraine. We believe that NeurAxon's NOS assets will find a profitable niche and we look forward to participating in the growth of NeurAxon Pharma for the benefit of patients and shareholders," stated Jonathan Ross Goodman, President and CEO of Knight.Dr. John S. Andrews, President of NeurAxon said "We are delighted to be able to secure
 <a href="http://www.benzinga.com/pressreleases/15/01/m5114518/knight-therapeutics-inc-and-neuraxon-inc-form-partnership-for-the-comme">See full press release</a>

Press Releases

Knight Therapeutics, NeurAxon Form NeurAxon Pharma to Commercialize NeurAxon's Innovative Products

Ardelyx's ($ARDX) strides in the internal medicine sector have put it on a promising growth trajectory. The company has experienced solid growth an...

Ardelyx (ARDX) Beats Expectations in Q2 and Offers Promising Outlook

Knight Therapeutics reports Q3 results

Mackie Research Capital analyst Andre Uddin downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target Published first on T...

Knight Therapeutics downgraded to Hold from Buy at Mackie Research Capital

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mind Medicine (MNMD – Research Report), Knight Thera...

Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report) today and set a price target of C$6...

Stifel Nicolaus Keeps Their Buy Rating on Knight Therapeutics (KHTRF)

Stifel analyst Justin Keywood lowered the firm's price target on Knight Therapeutics (KHTRF) to C$6.25 from C$6.75 and keeps a Buy rating on the sh...

Knight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel

Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with a price target of C$9.00. D...

Knight Therapeutics: Strong Revenue Growth and Strategic Prospects Justify Buy Rating

Raymond James lowered the firm's price target on Knight Therapeutics (KHTRF) to C$7.50 from C$8 and keeps an Outperform rating on the shares. Publi...

Knight Therapeutics price target lowered to C$7.50 from C$8 at Raymond James

ARDX

KYKOF

MNMD

OKUR

Knight Therapeutics

Raymond James

Comments

Knight Therapeutics

Knight Therapeutics (KHTRF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga